Evidence map›Paper›PMID 28077650›Full record

ArticleJournal of virology2017

Melanin or a Melanin-Like Substance Interacts with the N-Terminal Portion of Prion Protein and Inhibits Abnormal Prion Protein Formation in Prion-Infected Cells.

Taichi Hamanaka, Keiko Nishizawa, Yuji Sakasegawa, Ayumi Oguma, Kenta Teruya, Hiroshi Kurahashi, Hideyuki Hara, Suehiro Sakaguchi, Katsumi Doh-Ura

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Recent Advances and Progress on Melanin: From Source to Application.International journal of molecular sciences · 2023
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Taichi HamanakaDepartment of Neurochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan.
Keiko NishizawaDepartment of Neurochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yuji SakasegawaDepartment of Neurochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ayumi OgumaDepartment of Neurochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kenta TeruyaDepartment of Neurochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hiroshi KurahashiDepartment of Neurochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hideyuki HaraDivision of Molecular Neurobiology, Institute for Enzyme Research, Tokushima University, Tokushima, Japan.
Suehiro SakaguchiDivision of Molecular Neurobiology, Institute for Enzyme Research, Tokushima University, Tokushima, Japan.
Katsumi Doh-UraDepartment of Neurochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan doh-ura@med.tohoku.ac.jp.
Tohoku University · JPTokushima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prion diseases are progressive fatal neurodegenerative illnesses caused by the accumulation of transmissible abnormal prion protein (PrP). To find treatments for prion diseases, we searched for substances from natural resources that inhibit abnormal PrP formation in prion-infected cells. We found that high-molecular-weight components from insect cuticle extracts reduced abnormal PrP levels. The chemical nature of these components was consistent with that of melanin. In fact, synthetic melanin produced from tyrosine or 3-hydroxy-l-tyrosine inhibited abnormal PrP formation. Melanin did not modify cellular or cell surface PrP levels, nor did it modify lipid raft or cellular cholesterol levels. Neither did it enhance autophagy or lysosomal function. Melanin was capable of interacting with PrP at two N-terminal domains. Specifically, it strongly interacted with the PrP region of amino acids 23 to 50 including a positively charged amino acid cluster and weakly interacted with the PrP octarepeat peptide region of residues 51 to 90. However, the

Indexed as

AnimalsCell LineMelaninsMiceNeuronsPrion DiseasesPrionsProtein BindingProtein Interaction MappingSurvival AnalysisMelaninsPrionsdrug discoverymechanisms of actionmelaninprions

Identifiers

PMID28077650
PMCPMC5331829
OpenAlexW2571811360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.